Results 161 to 170 of about 28,682 (177)

A Population (Registry) Based Analysis of the Impact of Bcr-Abl Specific Tyrosine Kinase Inhibition on Survival after Diagnosis of Philadelphia Chromosome Positive Chronic Myelogenous Leukemia..

Blood, 2008
Abstract Specific tyrosine kinase inhibition (TKI) of the bcr-abl fusion protein in Philadelphia chromosome positive chronic myelogenous leukemia (CML) was introduced into general use in 2000 after a plenary abstract presentation to ASH in December 1999.
A. Robert Turner, Joanne D Hewitt, Anmmd Kamruzzaman, Loree M. Larratt, Deborah A. Rusnak, Nanette Cox-Kennett, Andrew R. Belch   +6 more
openaire   +1 more source

Patterns of Clonal Evolution in Ph’-Positive Chronic Myelogenous Leukemia (CML) during Chronic Phase: Overall Incidence, Type, Multiplicity, Development Time, Effect on Subsequent Genetic Instability, Sokal Risk, Type of bcr/abl Transcript and Hematological Evolution.

Blood, 2006
Abstract Fifty-two kariotypic abnormalities additional to Philadelphia chromosome (Ph’) were documented at the time of diagnosis or during the course of the disease in 114 CML patients. Five were evaluated only once at the time of diagnosis, while 109 were repeatedly studied overtime during a median period of 138 (1–275)months.
Anna Marina Liberati, Emilio Donti, Erminia Gentileschi, Vincenzo Capparella, Marta Gubbiotti, Alessandra Bassetti, Giovanna Venti, Paolo Prontera, Ilaria Angeletti, Rita Emili, Lorenzo Falchi, Debora Luzi   +11 more
openaire   +1 more source

[Regression of the Philadelphia chromosome (bcr/abl)-positive myelo- and megakaryopoiesis after Imatinib (STI571) therapy in chronic myelogenous leukemia (CML)].

Der Pathologe, 2005
In chronic myeloid leukemia following therapy with Imatinib (STI571) hematologic and cytogenetic response is associated with conspicuous changes of bone marrow morphology. However, it is not known to which extent these alterations are accompanied by a loss of the bcr/abl translocation. To study regression of the leukemic cell population we recruited 14
J, Thiele, H M, Kvasnicka, E, Varus, S, Kriener, K, Engels, P, Staib, E S, Ollig, M, Griesshammer, C F, Waller, H, Pfeifer, A, Schmitt-Gräff   +10 more
openaire   +1 more source

Closely Related BCR/ABL Oncogenes Are Associated with the Distinctive Clinical Biologies of Philadelphia Chromosome Positive Chronic Myelogenous and Acute Lymphocytic Leukemia

1988
The study of oncogene activation in naturally occurring human leukemias provides a useful approach to define the range of growth regulatory mechanisms used by hematopoietic stem cells. Recent analysis of the structural changes created by the Philadelphia chromosome translocation [t(9;22) — (q34;q11)] shows that two alternative regions of the BCR gene ...
openaire   +2 more sources

A possible correlation between the type of bcr-abl hybrid messenger RNA and platelet count in Philadelphia-positive chronic myelogenous leukemia.

Blood, 1992
The Philadelphia (Ph1) chromosome, in which the hybrid bcr-abl gene is formed, is thought to be the initial event in chronic myelogenous leukemia (CML). The position of the breakpoint within the breakpoint cluster region (bcr) on Ph1 chromosome and the splicing pattern determine the species of the fused bcr-abl messenger RNA (mRNA).
K, Inokuchi, T, Inoue, A, Tojo, M, Futaki, K, Miyake, T, Yamada, Y, Tanabe, I, Ohki, K, Dan, K, Ozawa   +9 more
openaire   +1 more source

[Marked reduction of BCR-ABL fusion chromosome positive cells with interferon therapy combined with short-term imatinib in chronic myelogenous leukemia].

Gan to kagaku ryoho. Cancer & chemotherapy, 2003
A 71-year-old man with chronic myelogenous leukemia received interferon therapy for 21 months, but did not have complete cytogenetic response. Imatinib was then added to the former therapy. Imatinib was prescribed for only 12 days and discontinued because of severe erythema.
Atsushi, Ajima, Naoya, Takayama, Yuichi, Hasegawa, Hiroshi, Kojima, Toshiro, Nagasawa   +4 more
openaire   +1 more source

Human medicines European public assessment report (EPAR): Imatinib Actavis, imatinib, Leukemia, Myelogenous, Chronic, BCR-ABL Positive,Precursor Cell Lymphoblastic Leukemia-Lymphoma,Myelodysplastic-Myeloproliferative Diseases,Hypereosinophilic Syndrome,Dermatofibrosarcoma, Date of authorisation: 17/

Case Medical Research, 2019

semanticscholar   +1 more source

Human medicines European public assessment report (EPAR): Imatinib medac, imatinib, Precursor Cell Lymphoblastic Leukemia-Lymphoma,Dermatofibrosarcoma,Leukemia, Myelogenous, Chronic, BCR-ABL Positive,Myelodysplastic-Myeloproliferative Diseases,Hypereosinophilic Syndrome, Date of authorisation: 25/09

Case Medical Research, 2019

semanticscholar   +1 more source

Human medicines European public assessment report (EPAR): Imatinib Accord, imatinib, Precursor Cell Lymphoblastic Leukemia-Lymphoma,Dermatofibrosarcoma,Myelodysplastic-Myeloproliferative Diseases,Leukemia, Myelogenous, Chronic, BCR-ABL Positive,Hypereosinophilic Syndrome, Date of authorisation: 30/0

Case Medical Research, 2019

semanticscholar   +1 more source

Extramedullary BCR-ABL positive T-lymphoblastic leukemia in a patient with chronic myelogenous leukemia

Community Oncology, 2012
Mylene Go, Le Wang, JinMing Song, Rene Rubin   +3 more
openaire   +1 more source